Kakkis Emil D insider trades
Kakkis Emil D has filed 15 Form 4s with the SEC that we hold, all for Ultragenyx Pharmaceutical Inc. (RARE), as President & CEO, Director. Across all of them we count 0 purchases worth $0 and 11 sales worth $13.7M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($1.2M). The largest single trade was a sale of 73,434 shares of Ultragenyx Pharmaceutical Inc. worth $3.1M, dated 2025-03-03. The first filing on our record is dated 2021-10-18 and the latest 2026-04-20.
Ultragenyx Pharmaceutical Inc. (RARE)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-12-30 | S, sale reported on Form 4 | 19,582 | $892.4K | 2023-01-03 |
| 2023-10-19 | S, sale reported on Form 4 | 47,853 | $1.6M | 2023-10-23 |
| 2023-12-29 | S, sale reported on Form 4 | 30,000 | $1.4M | 2024-01-02 |
| 2024-02-07 | S, sale reported on Form 4 | 30,000 | $1.4M | 2024-02-08 |
| 2024-08-06 | S, sale reported on Form 4 | 20,000 | $1.0M | 2024-08-07 |
| 2024-09-03 | S, sale reported on Form 4 | 20,000 | $1.1M | 2024-09-05 |
| 2024-12-10 | S, sale reported on Form 4 | 8,273 | $413.6K | 2024-12-11 |
| 2024-12-30 | S, sale reported on Form 4 | 11,727 | $495.2K | 2024-12-31 |
| 2025-02-28 | S, sale reported on Form 4 | 25,000 | $1.1M | 2025-03-04 |
| 2025-03-03 | S, sale reported on Form 4 | 73,434 | $3.1M | 2025-03-04 |
| 2026-03-02 | S, sale reported on Form 4 | 54,404 | $1.2M | 2026-03-03 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1248093) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms